After having been diagnosed with myeloma in 2019, Vincent Claus got in touch with MPE and joined the Taskforce. In 2022, he joined the Advocate Development Programme (ADP) and has since then been involved in many patient advocacy efforts such as SISAQOL-IMI. Recently with the support of MPE, he launched a specific support group for younger myeloma patients (European Young Myeloma Patients Group). His main fields of interest are the youngest myeloma population, lobbying for early(er) diagnosis and equal treatment approaches across Europe.
AELCLÉS presents report highlighting the high socioeconomic impact of oncohaematological diseases in Spain
More than 65 per cent of people living with an oncohaematological disease experience a deterioration in their employment and financial situation. This is one of the key findings of a…

